Breaking News Bar

Business News and Information

The Daily Herald Market Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
Concert Pharmaceutic (NQ: CNCE)
13.42 USD  -0.20 (-1.47%)
Official Closing Price  /  Updated: 4:57 PM EST, Dec 13, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 142,257
Open 13.66
Bid (Size) 13.42 (28)
Ask (Size) 13.43 (2)
Prev. Close 13.62
Today's Range 13.28 - 13.80
52wk Range 10.80 - 30.71
Shares Outstanding 23,395,816
Dividend Yield N/A
Performance
YTD
-50.72%
-50.72%
1 Month
+6.59%
+6.59%
3 Month
-4.62%
-4.62%
6 Month
-30.25%
-30.25%
1 Year
-48.38%
-48.38%
Top News
More News
Report: Exploring Fundamental Drivers Behind Sterling Construction, Tredegar, j2 Global, Medical Transcription Billing, Concert Pharmaceuticals, and Senseonics — New Horizons, Emerging Trends, and Upc
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Sterling Construction... Read More
from GlobeNewswire News Releases
Concert Pharmaceuticals Reports Positive CTP-543 Results from Interim Analysis of Phase 2a Trial in Patients with Alopecia Areata
At 24 weeks, patients treated with an 8 mg twice-daily dose of CTP-543 met the primary efficacy endpoint vs. placebo. Read More
from Business Wire News Releases
More News
Read More
Detailed Research: Economic Perspectives on Graco, Immunomedics, Concert Pharmaceuticals, Macquarie Infrastructure, Systemax, and Service Corporation International — What Drives Growth in Today's Comp
from GlobeNewswire News Releases
Concert Pharmaceuticals to Participate at Upcoming Investor Conferences
from Business Wire News Releases
Top Buys by Directors: Aldrich's $591.3K Bet on CNCE
category Stocks
from Market News Video
Concert Pharmaceuticals Presents Preclinical Data on CTP-692, a Novel Drug Candidate for Schizophrenia, Supporting Potential to Improve Safety Profile of D-Serine
from Business Wire News Releases
Friday 11/16 Insider Buying Report: WYNN, CNCE
category Stocks
from Market News Video
Concert Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Company Update
from Business Wire News Releases
Concert Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 1, 2018
from Business Wire News Releases
Analysts Expect EXT To Hit $37
category ETFs
from ETF Channel
Concert Pharmaceuticals Amends Protocol of Phase 2a Trial to Evaluate 12 mg Twice-Daily Dose Cohort of CTP-543 for the Treatment of Alopecia Areata
from Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account